



Index

A

- AccuMed International (AI), 89
- Acer Laboratories, 101
- Additive Control and Measurement Systems, Inc. (court-awarded royalty rate), 164
- Advanced Oxygen Technologies (AOT), 87
- After-tax income saved, discounting, 160
- Ajinomoto* ruling, district court writings, 38
- Alfimeprase, rights (sale), 21
- Allied Energy, 71
- Altria Group, advertising spending, 11e
- Alza, Johnson & Johnson purchase, 21–22
- Alzheimer's diagnostic test, license deals, 95e
- American Express, megabrand ranking, 12e
- American Innovations (AI), 86
- American Water Star (AWS), 113
- Ampersand Medical, 89
- Analysis Group, study, 54–55
- Andretti™, royalty statistics, 111
- AOT. *See* Advanced Oxygen Technologies
- Apparel, royalty statistics, 107–109
- Apple operating system (Apple OS), technology royalty statistics, 80–81
- Applied Nanotech (AN), 85
- Arm's length intercompany transactions, requirement, 182
- Arm's length negotiation, 62
- Artwork, royalty statistics, 109–112
- Asphalt roofing debris recycling, technology royalty statistics, 103
- AT&T, patent number, 5e
- AT&T Wireless, megabrand ranking, 12e
- Auditor selection, 191–192
- Audits. *See* Desk audits; Royalty audits
- Automotive industry, technology royalty statistics, 67–70
- Automotive manufacturing industry, technology royalty statistics, 69–70
- AWG, license agreement, 111

B

- Bard, C.R. (court-awarded royalty rate), 164e
- Battery terminals, technology royalty statistics, 68

- Bayer AG, patent number, 6e
 Benazepril, generic drug savings, 129e
 Benihana Japanese restaurants, royalty statistics, 118
 Berkman, Mark, 42
 Best Buy, megabrand ranking, 12e
 Biacore AB, court-awarded royalty rate, 164e
Biacore v. Thermo Bioanalysis, 172
 Big League Chew, royalty statistics, 111
 Biotechnology
 license deals, fees, 95e
 patent transfers, royalty rates, 97
 royalty rates, 58–60
 technology
 royalty statistics, 92–97
 transfers, royalty rates, 97
 Bloomberg database, 46
 BMS. *See* Bristol-Myers Squibb
 Book publishers, conglomerate ownership, 114–115
Bose v. JBL, 171
 Breast cancer detection, technology royalty statistics, 88–89
 Bristol-Myers Squibb (BMS)
 acquisition, 22
 Business enterprise
 equation, 119
 framework, 119–128
 illustration, 122e
 value
 equation, 120
 example, 147e
 Business groups, identification, 22–23
Business Week, reports, 129–130
 Buy-in payments, determination, 183
- C**
- Cancer screening, technology royalty statistics, 89
 Canon Kabushiki Kaisha, patent number, 5e
 Capital expenditure investments, timing/amount, 143
 Capital Grille Steakhouse, royalty statistics, 117–118
 CAS. *See* Computer Automation Systems
 Catheter, technology royalty statistics, 89–90
 CDMA. *See* Code Division Multiple Access
 Cell Robotics International (CRI), 90
 Centocor, biotech acquisition, 21
 Chemical companies, royalty rate guidelines, 54e
 Chemical industry, technology royalty statistics, 70–72
 Chemical manufacturers, focus, 70
Chemical Marketing Reporter, 130
 Chevrolet, megabrand ranking, 12e
 Chrysler. *See* DaimlerChrysler megabrand ranking, 12e
 Cingular, megabrand ranking, 12e
 Citibank, megabrand ranking, 12e
 Clark, Marcia (royalty statistics), 115
 Clearly Canadian Beverage Corporation, 86–87
 Clinical phases, approval success rates, 154e
 Clinical trial data/information, 121
 Clinton, Bill (royalty statistics), 115
 Clinton, Hillary Rodham (royalty statistics), 115–116
 Coca-Cola Company, trade secrets, 14–15
 Cochran, Johnnie (royalty statistics), 116
 Code Division Multiple Access (CDMA) technology, royalty statistics, 75

- Co-marketing agreements, 122
- 3Com Corporation, 78–79
- Commercialization
 expenses, 124
 FDA approval, phases, 152–153
 time-frame requirements, 124
- Commercial relationship, 28
- Commodity
 corporate value. *See* Generic
 commodity corporate value;
 Mature commodity corporate
 value
 earnings, 122–123
- Communications equipment/services,
 technology royalty statistics,
 72–76
- Company patents, number, 5e–6e
- Comparative analysis, summary, 65–66
- Competitive advantage, creation, 23
- Complementary assets, benefits, 124
- Computer
 architecture, technology royalty
 statistics, 77
 hardware, technology royalty statistics,
 76–80
 manufacturing, royalty rates
 (litigation/non-litigation
 comparison), 178e
 software, technology royalty statistics,
 80–82
 technology royalty statistics. *See* PS/2
 computers
- Computer Automation Systems (CAS),
 77–78
- Condiment names, royalty statistics, 112
- Construction industry, technology
 royalty statistics, 82–83
- Consumer reactions, 124
 change, 125
- Contraceptive regime alternative, license
 deals, 95e
- Conveyed sales, 28
- Copyright Act (1976), 10–11
- Copyrights, 10–13
 royalty rates, 57–58
 royalty statistics, 107
- Corporate royalty rate, 149
- Corporate value, 1. *See also* Generic
 commodity corporate value
- Cost savings, impact, 123
- Cost-sharing arrangements, usage,
 183
- Cough medicine, license deals, 95e
- Court-awarded royalty rates, 163
 ranking, 163–165
- Cox, Richard, 97
- C.R. Bard v. Boston Scientific*, 171
- Cypress stem cells research, license deals,
 95e
- D**
- Dabek, Rose Ann, 97
- DaimlerChrysler
 advertising spending, 11e
 profit share, 67
- Dannon, royalty statistics, 111–112
- Data mining, technology royalty
 statistics, 81–82
- Daubert v. Merrill Dow Pharmaceuticals*, 42
- Davis, Albert S., 33
- DCF. *See* Discounted cash flow
- DeCecco, Dave, 15
- Decision technology, royalty statistics,
 81–82
- Dell Computers, 77
 megabrand ranking, 12e
- Dermatology products, license deals, 95e
- Design patents, 3
- Desk audits, 193
- Detection monitoring, technology
 royalty statistics, 85

- Diabetes treatment, license deals, 95e
- Digital Information Communications and Electronics (DICE)
 companies, IP development reasons, 23
 licensing
 income, generation, 24
 insights, 23
 payments, minimization, 24
 out-licensing, 24
 patents, importance, 23
- Digital scanner, technology royalty statistics, 90
- Discounted cash flow (DCF), 31
 analysis, 155
 performing, 40
 royalty rates, relationship, 143
 example. *See* Success rates
- Discount rate, determination, 157, 159
- Disney, royalty statistics, 108
- DNA binding invention, license deals, 95e
- Dodge, megabrand ranking, 12e
- Drug. *See* Patented drugs
 development stages, value, 155e
 discovery, difficulty, 19, 92
 introduction, cost, 19
 inventions, dominance, 6
 market share, worth, 96
- DSL modems, demand, 72
- DVD/video players, technology royalty statistics, 84
- E**
- Early-stage technology, 29, 59
- Earnings
 capitalization, 31
 distribution, 121e, 134e
 revenue percentage. *See* Excess earnings
- Eastman Kodak, patent number, 5e
- Eating-and-drinking establishments
 characteristic, 117
 small business, frequency, 117
- Economic benefits
 competitor efforts, impact, 124
 derivation. *See* Technology
 duration, 125
 receiving, risk, 125
 time period, 143
- Economic factors, identification, 124–125
- Economic life, remainder. *See* Property
- Economic returns, receiving (risk), 124
- Economic risk, 125
- Eggs, technology royalty statistics, 87–88
- E.I. DuPont De Nemours, patent number, 6e
- Electronic Billboard Technology (EBT), 85
- Electronic Data Gathering Analysis and Retrieval (EDGAR), 185
 archives. *See* Securities and Exchange Commission
- Electronics
 product manufacturing, royalty rates (litigation/non-litigation comparison), 178e
 royalty rate guidelines, 54r
 technology royalty statistics, 84–86
- Eli Lilly, 114
- Enalapril, generic drug savings, 129e
- Entire market value rule, 170–171
- Environmental Solution Agency (ESA), 104–105
- Equity positions, 181
- Ericsson, 76
- Ernst and Young, report, 20
- Established trademarks, 121
- Everlast™, royalty statistics, 108
- Excess earnings, revenue percentage, 136e

Exclusive licenses, 122
 Exclusivity, 64–65. *See also* Licensing
 aspects, comparison, 66
 Expected profits
 focus, 34
 margin, equation, 125
 Expert testimony, importance, 169–170

F

Fabrics, royalty statistics, 109
 Fair market royalty
 establishment, 65–66
 negotiation, 65
 Fiberchem, 85
 Financial compliance
 monitoring, 187–189
 perceptions, 189
 Fixed assets, 137–139
 inclusion, 120
 investment return, earning, 131
 return, 137–139
 Fixed capital, illustration, 122e
 Flame-retardant products, technology
 royalty statistics, 71
 Flat panel display technology, royalty
 statistics, 85
 Fluoxetine, generic drug savings, 129e
 Food, household expenditures, 117
 Food and Drug Administration (FDA)
 approval, 149, 153
 phases. *See* Commercialization
 regulatory approvals, 122
 Food/beverage industry
 packaging, technology royalty
 statistics, 87
 technology royalty statistics, 86–88
Forbes, Naprosyn patent protection
 report, 130
 Ford Motor Co.
 advertising spending, 11e

 megabrand ranking, 12e
 profit share, 67
 Forecast revenue, 157, 158
Frank A. Calabrese v. Square D., 170
 Fuel reactor technology, technology
 royalty statistics, 71–72
 Fuel technology, technology royalty
 statistics, 72
 Fuji Photo Film, patent number, 6e
 Fujitsu, patent number, 6e
 Fully-loaded profits, 34–35
 Furosemide, generic drug savings, 129e

G

GAAP. *See* Generally accepted
 accounting principles
 GE-Harris Railway Electronics, LLC
 (court-awarded royalty rate),
 164e
 GEM Edwards, 90–91
 General Electric Co.
 advertising spending, 11e
 patent number, 5e
 Generally accepted accounting
 principles (GAAP), 190
 General Motors Corp.
 advertising spending, 10, 11e
 megabrand ranking, 12e
 profit share, 67
 General profit margins, 128
 Generic commodity corporate value,
 146–149
 Generic drugs
 companies, operating profit margins,
 127e
 savings, 129e
 Generic pricing, 128–131
 Genetic research, license deals, 95e
Georgia-Pacific v. U.S. Plywood, 40, 170
 Gift wrap, royalty statistics, 109

Gingrich, Newt (royalty statistics), 116
 GlaxoSmithKline, advertising spending,
 11e
Glenayre Electronics v. Philip Jackson et al.,
 168
 Glyburide, generic drug savings, 129e
 GNB Battery Technologies, 68
 Goldscheider, Robert, 31–33
 Greeting cards, royalty statistics, 109
 Gross cash flow, calculation, 145

H

Hawaiian Tropic®, royalty statistics, 113
 Hayes Microcomputer Products,
 79–80
 Healthcare, licensing insights, 23
 Health Technologies International
 (HTI), 88–89
 Hepatitis A vaccine, license deals, 95e
 Hewlett-Packard, megabrand ranking,
 12e
 High-bandwidth chip connection
 technology, royalty statistics,
 98–99
 Hitachi, patent number, 5e
 HIV/AIDS medicines, price
 comparisons, 130–131
 Home Depot
 advertising spending, 11e
 megabrand ranking, 12e
 Honda, megabrand ranking, 12e
 Honeywell International, Inc. (court-
 awarded royalty rate), 164e
*Honeywell International et al. v. Universal
 Avionics, Inc.*, 165
 Household items, royalty statistics, 109
 Hughes Danbury Optical Systems
 (HDOS), 99
 Hydro Environmental Resources
 (HER), ECHFR system, 71
 Hypoix tumor cell radiosensitizer,
 license deals, 95e

I

IBM, patent number, 5e
 Illinois Trade Secrets Act, 13
 Income taxes, 145
 calculation, 160
 Incremental savings, 38
 Independent publishers/bookstores,
 competition, 115
 INDS, first filing, 154e
 Industrial companies, licensing insights,
 23
 Industriy categorization, 56
 Industry litigated royalties, 179e
 Industry profits, 46
 rate, 147e
 Industry transactions, relevance, 63–64
 Inflationary risk, 125
 Influenza drug, license deals, 95e
 Information
 knowledge, 14
 secrecy, guarding, 14
 source, 182
 value, 14
 Infringement damages analysis, 125–128
 analytical approach, 125–126
 example, 126–127
 Intangible assets
 growth (1975–2005), 2e
 illustration, 122e
 required return, example, 137e
 return, 139
 Intangible property
 licensing, royalty rates (finding), 182
 valuation, 183
 Integrated Paving Concepts, 83
 Integrated Process Equipment
 Corporation (IPEC), 99

- Intellectual Property Association (IPA), 73
- Intellectual property (IP), 1
 contribution, operating profit level (accuracy), 35
 disputes, damages (establishment), 183
 dominance, 2
 illustration, 122e
 investment, timing/amount, 143
 involvement, 65, 66
 licensing, 17, 24
 out-licensing, 24
 required return, example, 137e
 return, 139
 valuation, Twenty-Five Percent Rule (usage), 31
 value, primary forces, 124–125
- Intellectual Property Research Associates (IPRA), 183
- Interactive Pictures v. Infinite Pictures*, 170
- Inter-company licenses, 62
- Interline Resources, 103
- Internal licenses
 identification, 65
 self-serving behavior, 62
- Internal research and development pipelines, insufficiency, 19, 92
- International transactions, 64
- Internet publishers, competition, 115
- Investment rate of return
 analysis, benefits, 140–141
 principles, 133–134
 royalty rates, 134–135
 relationship, 133
- Investment return, earning. *See* Fixed assets
 allowance, 141
- Investment risk, consideration, 140
- IP. *See* Intellectual property
- IPA. *See* Intellectual Property Association
- IPassets, development reasons, 23–24
- IPRA. *See* Intellectual Property Research Associates
- Issued patent, worth, 96
- IXYS, 101
- J**
- J.C. Penney, megabrand ranking, 12e
- Johnson & Johnson
 biotech acquisition, 21
- Johnson & Johnson, advertising spending, 11e
- Jones Medical Industries, 114
- K**
- Kaisha, patent number, 5e
- Kunho Tire Co. v. Carmichael*, 42
- L**
- Laser finger-perforator technology, royalty statistics, 90–91
- Laser hair removal, technology royalty statistics, 91–92
- Later-stage technology, risk, 28–29
- Law Relating to Inventions Made by Employees (Germany), 54
- Lee, William, 43, 44
- Leon B. Rosenblatt Textiles v. Griseto*, 110
- Library of Congress, 12–13
- License agreements
 drafting, 193–194
 monitoring, 187–189
 perceptions, 189
- Licensed product, distribution channels, 191
- Licensed royalty rates, 47e

- Licensee profits, 46–48
 1999–2000, 48e
 relationship. *See* Royalty rates
 splits, distribution. *See* Profit
 success. *See* Successful licensees
- Licensees
 business, contact person, 191
 internal controls, 191
- Licenses. *See* Package licenses
 comparison, 61
 fees, distribution, 59e
 rights, transfer, 65
 royalties, court determination,
 167–169
 self-serving behavior. *See* Internal
 licenses
 underreported royalties, percentage,
 188e
- Licensing. *See* Intellectual property
 agreement royalty rate frequency,
 59e
 company engagement, reasons,
 25–29
 exclusivity, 25
 forces, 19–22
 motivation, 22–24
 parties, financial condition, 63
 protection, 25
 utility, 25
- Licensor/licensee communications, 195
- Lightning resistance, technology royalty
 statistics, 99
- Lisinopril, generic drug savings, 129e
- Litigated licenses, non-litigated licenses
 (comparison), 175–180
- Litigation rates, increase, 175
- Long-run product profits, expectation,
 45
- L'Oreal, advertising spending, 11e
- Lotto™, royalty statistics, 108
- Lucky-Goldstar Group, 83
- M**
- Machinery, royalty rate guidelines, 54r
- Macintosh enhancement, technology
 royalty statistics, 77
- Macy's, megabrand ranking, 12e
- Mahurkar, Sakharam D. (court-awarded
 royalty rate), 164
- Management competency, 124
- Manufacturing, technology royalty
 statistics, 99–100
- Manufacturing industries
 royalty income, 18
 technology royalty statistics. *See*
 Automotive manufacturing
 industry
- Market acceptance, 155
- Marketing expenses, 145
- Market risk, 125
- Market share, expansion (impact), 123
- Marks. *See* Trademarks
- Massachusetts General Hospital (MGH),
 92
- Matsushita Electric Industrial, patent
 number, 5e
- Mature commodity corporate value,
 146–149
- McDonald's Corp.
 advertising spending, 11e
 megabrand ranking, 12e
- Medical equipment
 royalty rates, litigation/non-litigation
 comparison, 178e
 technology royalty statistics, 88–92
- Medical supplies, royalty rates (litigation/
 non-litigation comparison),
 178e
- Medicinal, Chemicals and Botanical
 Products (SIC #2833), 128
- Medius Associates, 94
- Merck & Co., advertising spending,
 11e

- Metformin, generic drug savings, 129e
- Meyer III, Harold A. (royalty rate guideline suggestions), 96
- MichellamineB/tropical vine leaves, license deals, 95e
- Mickowski v. Visi-Trak Corporation et al.*, 168
- Mikohn Gaming Corporation, court-awarded royalty rate, 164e
- Mikohn Gaming v. Acres Gaming, Inc.*, 165
- Mineral water, technology royalty statistics, 86–87
- Mitsubishi Denki Kabushiki, patent number, 5e
- Mitutoyo Corporation, court-awarded royalty rate, 164e
- Mitutoyo Corporation et al. v. Central Purchasing, LLC*, 165
- Modems
standards, technology royalty statistics, 78–79
technology royalty statistics, 79–80
- Modified Black-Scholes option valuation methods, 31
- Modine Manufacturing Company, court-awarded royalty rate, 164
- Monetary assets, return, 136–137
- Monte Carlo simulation, 31
- Motorola, patent number, 5e
- MPEG LA, 74–75
- N**
- NAICS. *See* North American Industry Classification System
- NCEs. *See* New chemical entities
- NEC, patent number, 5e
- Nestor Traffic Systems (NTS), 81
PRISM® fraud detection solutions, 82
- Net cash flow calculation, 144
- Net present value. *See* Risk adjusted net present value
- Neupogen, license deals, 95e
- New chemical entities (NCEs), 152. *See also* Self-originated NCEs submission, 153
- New compound, valuation, 156e
- New molecular entities (NMEs), 152
- New product, licensed technology basis (example), 148e, 150e, 151e
- New product revenue forecast, example, 127e
- New Restatement of the Law Third, Unfair Competition, 13
- Nissan Motor Co.
advertising spending, 11e
megabrand ranking, 12e
Samsung Group sale, 69
- NMEs. *See* New molecular entities
- Nokia, 76
- Non-cash expense, 145
- Non-exclusive licenses, 122
- Non-licensed IP, earnings, 140
- Non-litigated licenses, comparison. *See* Litigated licenses
- Non-monetary compensation, 64
- Normal profit margin, equation, 125
- North American Industry Classification System (NAICS), 166
- Northeast American Enterprises, 77
- Notes, 197–203
- Novartis, advertising spending, 11e
- NTS. *See* Nestor Traffic Systems
- NTT DoCoMo, 76
- Nucleic acid probe technology, license deals, 95e
- Nuvelo, commercialization rights, 21

O

Odetics, federal circuit court writings, 38

Operating profits, 35, 145

level, accuracy. *See* Information

Processing

margins. *See* Generic drugs

rate, expectation, 40

Out-licensing. *See* Digital Information

Communications and

Electronics; Intellectual property

Overhead expenses, 145

omission, 35

P

Package licenses, 65

Packaging, technology royalty statistics.

See Food/beverage industry

Palomar Medical Technologies, 91

Patented drugs, 121

Patented invention

remaining life, 160

royalty rate, 140

Patented technology valuation, relic

from-royalty method, 155–157

Patented therapeutic drugs, royalty rate

(example), 138e

Patents, 3–8. *See also* Design patents;

Plant patents; Utility patents

applications, 121

history. *See* United States patents

importance. *See* Digital Information

Communications and Electronics

number. *See* Company patents

owner distribution, 5e

ownership, identification, 4–6

pending, worth, 96

protection, remaining life

(determination), 157–158

prototype, presence (worth), 96

risks, validity, 125

technology classifications, 6. *See also*

United States patents

transfers, royalty rates. *See*

Biotechnology

trends, 4

types, 3

worth. *See* Issued patent

Patent to Profit, guidance, 53–54

Paving, technology royalty statistics,

83

Pentium II processor, technology royalty

statistics, 100–101

PepsiCo, advertising spending, 11e

Pepsi-Cola, trade secrets, 14–15

Personal care, royalty statistics,

112–114

Personal digital assistant (PDA), patent

example, 4

Pfizer, advertising spending, 11e

Pharmaceutical Business News, 130

Pharmaceutical companies

(pharmaceuticals)

competition, 19, 93

compound (discovery), pressure

(increase), 19, 92

development stage, royalty rate, 94

intangible assets, 121–122

intellectual property, 121–122

invention, category, 94

license deals, fees, 95e

research and development

deficiencies, licensing activity

supplement, 93

stage, average royalty, 96

royalty rates, 58–60

distribution, 94e

guidelines, 54e

information, 26–27

technology royalty statistics, 92–97

Pharmaceutical drug, clinical trials

(worth), 96

- Pharmaceutical industry
 development stage, royalty rate, 96
 royalty rates, increase, 19, 92–93
- Pharmaceutical preparations (SIC #2834), 128
- Pharmaceutical Research and Manufacturers of America (PhRMA), 153
- Plant patents, 3
- Polo, royalty statistics, 108–109
- Polyvinyl chloride pipe products, technology royalty statistics, 83
- Posters, royalty statistics, 109
- Post-site analysis/report generation, 192
- Power conversion, technology royalty statistics, 101
- Precision Materials Operation (PMO), 99
- Present value calculation, 160–161
- Pre-site research, 192
- Pretax profits, 35
- Price premiums, obtaining, 122–123
- Prints, royalty statistics, 109
- Probability-of-success factor, 152
- Procter and Gamble v. Paragon Trade Brands*, 44
- Procter & Gamble Co.
 advertising spending, 10, 11e
 licensing restrictions, 158
- Product commercialization, expenses, 145
- Production efficiencies, 124
- Product revenue
 forecast, example. *See* New product revenue forecast
 patent enhancement, 37
- Profit. *See* Industry profits; Licensee profits; Operating profits
 amount, 124
 differentials, royalty rates (relationship), 119
 duration, 124
 expectation, risk (association), 124
 margins. *See* General profit margins equation. *See* Expected profits; Normal profit margin
 rates. *See* Industry profits
 splits, licensee profits (distribution), 49e, 51e
 twenty-five profit, rule of thumb, 42
- Projections, usage, 170
- Promega v. LifeCodes Corporation et al.*, 168
- Promotion agreements, 122
- Property, economic life (remainder), 40
- Protection, duration, 27–28
- PS/2 computers, technology royalty statistics, 77–78
- Publishing
 houses, complaints, 114
 royalty statistics, 114–116
- Purchase price allocation, determination, 182
- Q**
- Qualcomm, 74, 75
- R**
- Ralph Lauren, royalty statistics, 108–109
- Ramtron International, 101
- Rare Hospitality, 117–118
- Raw idea, worth, 96
- Razgaitis, Richard, 41
- ReClaim, 103
- Recycling, 102
- Red flags, 190–191
- Regulatory risk, 125

- Relief-from-royalty method
 inputs, 157
 usage. *See* Patented technology valuation
- Remote metering, technology royalty statistics, 86
- Research expenses, 145
- Research Frontiers, 70
- Restatement of Torts, 13
- Restaurants
 consumer spending, 117
 industry, impact (expectation), 116
 royalty statistics, 116–118
 sales, job generation, 117
- Return. *See* Investment rate of return
- Return on investment, 31
- Revenue, growth expectation, 160
- Risk adjusted net present value, 149–153
- Risk Management Association (RMA)
 Annual Statement Studies, 128
- Risk reduction, consideration, 138
- Rite-Hite Corporation et al. v. Kelley Corporation*, 167–168
- Royalties
 determination, Sixth Circuit Court of Appeals (impact), 33
 factors, 25e
 income. *See* Manufacturing industries
 IRS report, 17–18
 miscalculations, recurrence, 191
 reasonableness, court considerations, 167–171
 recipients, ranking, 97
 saving, 160
 statistics. *See* Technology
 terms
 inclusion, 66
 specification, 66
- Royalty audits
 defining, 190–191
 errors, 194–195
 mistakes, likelihood (decrease), 193–194
 monitoring program, benefits, 195–196
 process, 192–193
- Royalty rates, 45–46. *See also*
 Biotechnology; Copyrights;
 Corporate royalty rate; Court-awarded royalty rates; Licensed royalty rates; Technology;
 Trademarks
- appropriateness, 135–137
 awards
 frequency, 165–166
 industry categorization, 167e
 ranking, 164e
 reasonableness, 176e
 details, 181
 district court awards, 166e
 equation, 125
 federal circuit decisions, 171–173
 finding. *See* Intangible property
 frequency, 57e. *See also* Licensing;
 Trademarks
- guidelines, 53. *See also* Pharmaceutical companies
 ranking, 54e
 industry categorizations, 166–167
 input, determination, 157, 158–159
 licensee profits, relationship, 48–51
 ranking, 49e
 litigation, non-litigation (comparison), 177e
 percentage, 56
 primary factors, 124–125
 relationship. *See* Discounted cash flow analysis; Profit
 services, 181
 successful licensee profits, relationship, 50–51
 ranking, 50e

Royalty Rates for Pharmaceuticals and Biotechnology, 26–27, 58, 183–184

Royalty Rates for Technology, 55, 184

Royalty Rates for Trademarks and Copyrights, 57, 184

RoyaltySource®, 93, 181–182
 data, Analysis Group study, 56
 information, 45–46
 royalty rates, 55e

RoyaltyStat®, 182–183
 usefulness, 182–183

Ruth's Chris Steakhouse, royalty statistics, 117

S

Sakharam D. Mahurkar v. C.R. Bard, 172

Samsung Group, sale, 69

SBC Communications, advertising spending, 11e

Scantek Medical, 88–89

Schaafsma, Paul, 42

Scientific databases, 121

SciMed Life Systems, 89

Sears, megabrand ranking, 12e

Sears Holdings Corp., advertising spending, 11e

Securities and Exchange Commission (SEC) EDGAR Archives, 182, 184–185

Segan Limited Partnership v. Trendmasters, 169

Self-dimmable rearview mirrors, technology royalty statistics, 70

Self-interests, argument, 62

Self-originated NCEs, 154e

Selling expenses, 145

Semiconductors, technology royalty statistics, 97–102

Sharer, Kevin, 20

SI Diamond Technology, 85

Siemens AG, patent number, 5e

Sign Builders of America (SBOA), 85

Silicon Integrated Systems (SIS), 100

Single inline memory modules (SIMMs), technology royalty statistics, 102

Site investigation, 192

Skoda Klatovy, 104

Slimfold Manufacturing Company v. Kinkead Industries, Inc., 165

Smithkline Diagnostics, Inc. (court-awarded royalty rate), 164e

Sony Corp.
 advertising spending, 11e
 patent number, 5e

Spirulina, license deals, 95e

Spring, megabrand ranking, 12e

Standard Manufacturing and DBP v. United States, 40

Standard & Poor's 500 (S&P500)
 company assets (1975–2005), 2e

Subject analysis, 65

Successful licensees
 profitability data, 50
 profits, 50

relationship. *See* Royalty rates

Success rates, 153–154

adjusted DCF example, 155–156
 adjusted present value calculations, usage, 156e

therapeutic class, identification, 154e

Sugar Foods, 112

Sunk costs, 34

T

Tangible assets, return, 137–139

Tanning Research Laboratories, 113

Tapazole®, royalty statistics, 114

Target stores, megabrand ranking, 12e

- Tax law compliance, 182
- Tax rate, determination, 157, 159
- Technology
- alternatives, 125
 - classifications. *See* Patents; United States patents
 - economic benefits, derivation, 124
 - obsolescence, 125
 - risk, 125
 - royalty
 - rates, 55–57
 - statistics, 67
 - transfers, royalty rates. *See* Biotechnology
- Territory restriction, 27
- Textile patterns, royalty statistics, 110
- Thin film ferroelectric technology, royalty statistics, 101–102
- Third-generation wireless technology, technology royalty statistics, 73–74
- Time period, relevance, 62–63
- Time Warner, advertising spending, 11e
- Tire recycling, technology royalty statistics, 104–105
- Titan Technologies, 104
- T-Mobile, megabrand ranking, 12e
- Toikka, Richard, 42
- Toshiba, patent number, 5e
- Total Containment v. Environ Products*, 172
- Total earnings, 135
- Total market, intangible value (percentage), 2e
- Toyota Motor Corp.
 - advertising spending, 11e
 - megabrand ranking, 12e
- Toys/dolls, royalty statistics, 109
- TP Orthodontics, Inc. (court-awarded royalty rate), 164
- Trademarks (marks), 8–10. *See also* Established trademarks
- applications, 9
 - foreign nation filers, 10e
 - applications (2005), 9
 - royalty rates, 57–58
 - frequency, 58e
 - royalty statistics, 107
- Trade secrets, 13–15
- evaluation, 14–15
- Transaction terms, 182
- Transaxles, technology royalty statistics, 68–69
- Transfer pricing regulations, 183
- Tristrada Technology, Inc. v. Mary Kay, Inc.*, 168
- Twenty-Five Percent Rule
- application, 39–41
 - criticisms, 42–44
 - empirical test, 44–45
 - employment, 40
 - explanation, 33–36
 - history, 32–33
 - illustration, 36–39
 - cost side, 38e
 - revenue side, 37e
 - indeterminateness, 43
 - justification, 41–42
 - rule of thumb, 42, 44
 - usage. *See* Intellectual property
 - introduction, 31–32
- TWM Manufacturing v. Dura Corporation*, 126
- ## U
- UMTS. *See* Universal Mobile Telecommunications System
- Unilever, advertising spending, 11e
- Unisplay v. American Electronic Sign*, 172

United Fire Technology (UFT), 71
 United States advertisers, ranking, 11e
 United States government, advertising spending, 11e
 United States megabrands, ranking, 12e
 United States Navy, patent number, 6e
 United States Patent and Trademark Office (USPTO), 3
 registration, 8
 United States patents
 applications
 1850–2004, 8e
 history, 6–8
 technology classification, 7e
 Universal Mobile Telecommunications System (UMTS), 73–74
 University/government licensing
 insights, 23
 Unocal Corporation, lawsuit, 72
 Up-front payments, 181
 Used oil recovery, technology royalty statistics, 103–104
 US Philips, patent number, 5e
 Utility patents, 3

V

Valero Energy, lawsuit, 72
 Valuation. *See* Patented technology valuation
 relief-from-royalty method, 160e
 Verapamil hcl SR, generic drug savings, 129e
 Verizon Communications
 advertising spending, 11e
 megabrand ranking, 12
 Vidal Sassoon, royalty statistics, 114
 Video patent pool, technology royalty statistics, 74–75

W

WACOC. *See* Weighted average cost of capital
 Wal-Mart, megabrand ranking, 12e
 Walt Disney Co., advertising spending, 11e
 Warfarin, generic drug savings, 129e
 Wart removal products, license deals, 95e
 Waste management, technology royalty statistics, 102–105
 Water-jel burn dressings, license deals, 95e
 Weighted average cost of capital (WACOC), 159
 Weiler, David, 95
 Wideband code division multiple access (W-CDMA) technology, royalty statistics, 76
 Williams, Lonnie (court-awarded royalty rate), 164
 Windows operating system (Windows OS) code, technology royalty statistics, 82
 Working capital (WC), 135
 illustration, 122e
 investments, timing/amount, 143

X

Xerox, patent number, 6e

Y

YoCream, royalty statistics, 111–112

Z

Zygo Corporation, court-awarded royalty rate, 164

<http://www.pbookshop.com>